dr. bazhenova on new developments in ret-rearranged nsclc
Published 5 years ago • 158 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
3:05
advaned ret-rearranged nsclc
-
2:30
concerning kinases: therapeutic considerations for ret rearranged nsclc
-
1:12
dr. drilon on ret rearrangements in nsclc
-
2:21
pralsetinib in chinese patients with advanced ret fusion nsclc
-
3:18
arrow update confirms pralsetinib benefit for ret fusion-positive advanced nsclc | stephen liu
-
3:58
libretto-001: targeting ret fusions in advanced-stage nsclc
-
1:45
targeting ret in lung cancer
-
1:36
ensartinib for advanced alk rearranged non-small cell lung cancer
-
7:37
rare fusions in nsclc: ret - targeted therapies in lung cancer 2023
-
3:32
ret in lung cancer: the next big target?
-
6:42
selpercatinib benefit, with or without pembro, in first-line advanced ret fusion-positive nsclc
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
4:58
treatment of nsclc with ret fusions
-
5:45
subtypes in nsclc: braf and ret
-
1:12
phase ii results for cabozantinib in ret-rearranged lung cancer
-
3:31
ret as a target in lung cancer
-
7:20
arrow points the way for ret fusion-positive nsclc treatment | stephen liu
-
9:57
expert highlights: targeted therapy for alk-, ret- and met-driven nsclc | tejas patil
-
26:57
segment 2: molecular targets in nsclc